Cellectis Financial Update: Promising Advances in Gene Therapy
Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS) is making significant strides in the field of gene therapy, with promising results from its clinical programs. The company's flagship products, lasme-cel and eti-cel, have shown potential in treating patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and non-Hodgkin lymphoma (NHL), respectively.
Highlights from Clinical Trials
The clinical data presented by Cellectis indicates that both lasme-cel and eti-cel demonstrate their ability to induce profound and meaningful responses in patients suffering from challenging hematological malignancies.
Lasme-cel Efficacy in B-ALL
In the BALLI-01 study, lasme-cel showcased an overall response rate (ORR) of 68% amongst 22 patients treated with the Cellectis-produced product (Process 2). Notably, the response rate improved to 83% at the recommended Phase 2 dose for 12 patients, and it reached an impressive 100% in the designated Phase 2 population of nine patients.
Eti-cel Results in Non-Hodgkin Lymphoma
For the eti-cel product, preliminary data from the NATHALI-01 study revealed an ORR of 86% with a complete response rate of 57% in a subgroup of seven patients. These encouraging results position eti-cel as a potential game-changer in addressing r/r NHL.
Financial Position of Cellectis
As of September 30, 2025, Cellectis reported cash and cash equivalents totaling $225 million, providing the necessary financial runway to support operations through the second half of 2027. This strong liquidity highlights the company's capability to continue its clinical development activities and support the advancement of its pipeline.
Future Milestones and Expectations
Looking ahead, the company anticipates sharing further development updates at upcoming medical meetings such as the ASH 2025 Annual Meeting. The first interim analysis for the pivotal Phase 2 BALLI-01 trial is expected in late 2026, with the potential for a Biologics License Application (BLA) submission in 2028.
Innovation in Gene Editing
Cellectis continues to innovate in gene therapy, utilizing cutting-edge techniques such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to produce gene-edited therapies. Their proprietary approach has led to advancements in off-the-shelf CAR-T therapies, streamlining the treatment process for patients with severe conditions.
Collaborations to Enhance Research
In a strategic move, AstraZeneca engaged in a joint research and collaboration agreement with Cellectis to expedite the development of novel therapies targeting high unmet medical needs. This partnership is set to leverage the extensive gene-editing expertise of Cellectis to bring forth innovative products to the market.
Response to Competitive Landscape
The advancements and collaborations emphasize Cellectis' commitment to remain competitive in the thriving gene therapy market. With tangible results and strategic partnerships, Cellectis is aligned to address the urgent needs in cancer treatment using their proprietary technologies.
Frequently Asked Questions
What are lasme-cel and eti-cel used for?
Lasme-cel (UCART22) is designed for the treatment of relapsed or refractory B-ALL, while eti-cel (UCART20x22) targets relapsed or refractory non-Hodgkin lymphoma.
How is the financial health of Cellectis?
Cellectis holds approximately $225 million in cash and equivalents, which is projected to support operations through the end of 2027.
What were the key findings from the recent clinical trials?
Cellectis reported an overall response rate of 68% for lasme-cel in B-ALL and an ORR of 86% for eti-cel in NHL, indicating promising efficacy for both therapies.
What are the anticipated milestones for Cellectis?
The company expects to present additional data at the ASH 2025 meeting and plans to conduct the first interim analysis for the BALLI-01 trial in late 2026.
Who are Cellectis' strategic partners?
AstraZeneca has entered into a significant partnership with Cellectis to enhance the development of gene and cell therapies, focusing on high unmet medical needs.
